Can hepatitis C elimination targets be sustained among people who inject drugs post-2030
Bibliographic Data
| ID | 14907012 |
|---|---|
| Authors | Charlotte Lanièce Delaunay (0000-0002-7038-325X, McGill University Health Centre), Arnaud Godin (0000-0002-5823-3961, McGill University), Nadine Kronfli (0000-0003-2724-0496, McGill University Health Centre), Dimitra Panagiotoglou (0000-0003-4756-1721, McGill University), Joseph Cox (0000-0002-7041-1556, McGill University), Michel Alary (0000-0002-0246-4429, Université Laval), Marina B Klein (0000-0002-3063-8430, McGill University Health Centre), Mathieu Maheu-Giroux (0000-0002-8363-4388, McGill University, corresponding author) |
| Year | 2021 |
| Volume | 96 |
| Pages | 103343 |
| Publication date | 2021-10-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | International Journal of Drug Policy (JOURNAL) |
| Journal identifiers | ISSN: 0955-3959 • E-ISSN: 1873-4758 |
| Publisher | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.drugpo.2021.103343 |
| PMID | 34215459 |
| OpenAlex | W3175812728 |
| Language | EN |
| Citations received | 3 |
| References cited | 49 |
Despite ongoing transmission risks, HCV incidence rebounds slowly after 2030 under pre-2020 testing and treatment levels. This is heightened by maintaining high-coverage harm reduction interventions. Overall, sustaining elimination would require considerably less effort than achieving it
Environmental health · Harm reduction · Hepatitis C · Human immunodeficiency virus (HIV · Incidence (geometry · Population · Psychiatry · Psychological intervention · Transmission (telecommunications · Treatment as prevention · Viral load · Computer Science · Demography · Hepatitis B Virus Studies · Hepatitis C virus research · HIV, Drug Use, Sexual Risk · Medicine · Virology
Public health interventions, priority populations, and the impact of Covid-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada)
Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs
Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
Prevention of HIV infection for people who inject drugs
Supervised injection facilities in Canada
Opiate substitution treatment and HIV transmission in people who inject drugs
Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B
Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs
Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs
Retention, Antiretroviral Therapy Use and Viral Suppression by History of Injection Drug Use Among HIV-Infected Patients in an Urban HIV Clinical Cohort
The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada
The cost-effectiveness of harm reduction
Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada
| Unique citing works | 3 |
|---|---|
| Citations per year | 0,6 |
| Citation span | 2021 - 2023 (3) |
| Citation velocity | historical |
| Highly cited | No |
| Citation types | Neutral: 3 |